CJC-1295 vs KPV
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →KPV
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | KPV |
|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Inhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Oral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Can be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Generally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action. |
| Best For |